Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM74SVE)

Drug Name

Dasiglucagon Drug Info

Synonyms

UNII-AD4J2O47FQ; AD4J2O47FQ; Dasiglucagon [INN]; Dasiglucagon [USAN]; Dasiglucagon [WHO-DD]; Dasiglucagon [USAN:INN]; ZP-GA-1; ZP4207; ZP-4207; 1544300-84-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr; L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-alpha

Indication

Disease Entry	ICD 11	Status	REF
Hypoglycemia	5A41	Approved	[1]
Hyperinsulinemia	5A4Y	Phase 2	[2]

Cross-matching ID

PubChem CID: 126961379
CAS Number: CAS 1544300-84-6
TTD Drug ID: DM74SVE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glucagon receptor (GCGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucagon recombinant	DMFLUTR	Hypoglycemia	5A41	Approved	[3]
Retatrutide	DM8WU0Q	Obesity	5B81	Phase 3	[4]
MK-8521	DMVNAYE	Type-2 diabetes	5A11	Phase 2	[5]
LY2944876	DML6XWR	Diabetic complication	5A2Y	Phase 2	[6]
TT-401	DMRQ0SA	Type-2 diabetes	5A11	Phase 2	[5]
LGD-6972	DMPL9KG	Type-2 diabetes	5A11	Phase 2	[7]
PF-06291874	DMN94QM	Type-2 diabetes	5A11	Phase 2	[8]
LY-2409021	DMZOIP4	Type-2 diabetes	5A11	Phase 2	[9]
REMD 477	DM13OVF	Type-1 diabetes	5A10	Phase 2	[10]
Efinopegdutide	DMAN2V2	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon receptor (GCGR)	TT9O6WS	GLR_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2	ClinicalTrials.gov (NCT04836273) Treatment of Post-bariatric Hypoglycaemia (SHERRY). U.S. National Institutes of Health.
3	Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
4	Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
8	Clinical pipeline report, company report or official report of pfizer.
9	Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
10	Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
11	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.